<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444025</url>
  </required_header>
  <id_info>
    <org_study_id>B2017-11</org_study_id>
    <nct_id>NCT03444025</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Goserelin for Triple Negative Breast Cancer</brief_title>
  <acronym>NeoGONT</acronym>
  <official_title>Prospective Phase II Randomized Trial of Evaluating the Effect of Adding LHRH Analogue to the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer on Pathologic Complete Response (pCR) Rates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II randomized trial that will evaluate the effect of adding LHRH analogue,&#xD;
      goserelin, to the standard neoadjuvant chemotherapy to patients with triple negative breast&#xD;
      cancer. Targeting LHRH might decrease resistance to chemotherapeutic agents in the&#xD;
      neoadjuvant setting and increases clinical and pathological response rates. Additionally,&#xD;
      exploring potential surrogate markers (as AR and LHRH receptors) for molecular distinct&#xD;
      subtypes of TNBC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neoadjuvant chemotherapy (NACT) is the mainstay of treatment of locally advanced TNBC and&#xD;
      some selected early cases followed by surgery with or without adjuvant radiotherapy. NACT is&#xD;
      aimed to induce pathologic complete response (pCR) in tumor and lymph nodes, pCR is proofed&#xD;
      to be a surrogate and reliable predictive factor of survival rates in TNBC. This study will&#xD;
      evaluate the effect of adding LHRH analogue, goserelin, to the standard neoadjuvant&#xD;
      chemotherapy. Following completion of neoadjuvant therapy, patients will undergo breast&#xD;
      conservative surgery or mastectomy. Post-neoadjuvant chemotherapy axillary staging will be&#xD;
      required, but the choice of the procedure will be at the physician's discretion.&#xD;
      Postoperative radiation therapy will be given at the physician's discretion. The use of&#xD;
      partial breast irradiation techniques will not be allowed. The primary endpoint will be the&#xD;
      rate of pathologic complete response. The secondary endpoints will be 3-year-disease free&#xD;
      survival, clinical response and toxicity. Exploratory endpoints will be correlation of the&#xD;
      LHRH receptor expression level with the pCR. The sample size for the trial will be 180&#xD;
      patients accrued over a period of 2 years. Definitive analysis of the primary endpoints is&#xD;
      expected at year 3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete response rate</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint will be the pathologic complete response rate (pCR), defined as no residual invasive tumor in both the breast and axilla (and including in situ residual; ypT0/is, ypN0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LHRH-positive and/or AR-positive Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of LHRH-positive and/or AR-positive cases among TNBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Estimated 3 years RFS rates in the 2 arms (RFS events will include locoregional recurrence, distant recurrence, contralateral breast cancer and death from any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical and radiological ORRs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>All grade and high grade adverse events rate in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian failure rate</measure>
    <time_frame>2 years</time_frame>
    <description>Ovarian failure rates at 2 years in both groups (defined as the absence of menses in the preceding 6 months and levels of follicle-stimulating hormone (FSH) in the postmenopausal range).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Breast Cancer Triple Negative</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Goserelin 3.6 mg depot injection will be administered subcutaneously every month along with standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>Goserelin is Luteinizing hormone releasing hormone (LHRH) analogue.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Premenopausal women between 18 and 60 years.&#xD;
&#xD;
          2. Histologically proven, newly diagnosed invasive carcinoma of breast.&#xD;
&#xD;
          3. Tumors must be ER, PgR negative and HER2-neu negative.&#xD;
&#xD;
          4. Stage II or III breast cancer that is indicated for neoadjuvant systemic chemotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. pregnant females at time of diagnosis of breast cancer.&#xD;
&#xD;
          2. bilateral breast cancer.&#xD;
&#xD;
          3. already received treatment for breast cancer including surgery, radiation, cytotoxic,&#xD;
             or endocrine therapy&#xD;
&#xD;
          4. history or concomitant diagnosis of another primary malignancy.&#xD;
&#xD;
          5. concurrent treatment with oral contraceptives or hormone replacement therapy (OCPs or&#xD;
             HRT must be stopped at least 4 weeks prior to randomization).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>self-representation of gender identity</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyrillus S Shohdy, MD</last_name>
    <phone>02 01229961016</phone>
    <email>shohdyks@residents.kasralainy.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Loay Kassem, MD</last_name>
    <phone>02 01003022907</phone>
    <email>loay.kassem@cairocure.com</email>
  </overall_contact_backup>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 18, 2018</study_first_submitted>
  <study_first_submitted_qc>February 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>February 18, 2018</last_update_submitted>
  <last_update_submitted_qc>February 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Kyrillus S Shohdy</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

